指南与共识认知障碍与痴呆

轻度认知障碍实践指南更新摘要(已退休)

Practice guideline update summary: Mild cognitive impairment [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
指南 / 共识 · Neurology · 2017-12-27

该指南由美国神经病学学会(AAN)指南制定、传播与实施小组委员会对2001年版轻度认知障碍(MCI)指南进行更新,系统评价MCI患病率、预后与治疗证据,并结合改良Delphi共识形成推荐。MCI患病率随年龄增长而升高,65岁以上MCI患者2年累积痴呆发病率为14.9%;无高质量证据支持药物治疗,运动训练可能改善认知指标。

要点

  • 应使用经验证工具在合适场景评估MCI(B级)。
  • 应评估可调控危险因素、功能损害及行为/神经精神症状(B级)。
  • 应推荐规律运动(B级),可推荐认知训练(C级)。

核心结论

  • MCI患病率随年龄增长而升高,65岁以上MCI患者2年累积痴呆发病率为14.9%。
  • 无高质量证据支持MCI的药物治疗;运动训练(6个月)可能改善认知指标,认知训练可能改善认知指标。

研究设计与样本

  • AAN指南制定、传播与实施小组委员会系统评价MCI患病率、预后与治疗文献,按AAN证据分类标准分级,并结合改良Delphi共识形成推荐。

主要发现

  • MCI患病率:60-64岁为6.7%,65-69岁为8.4%,70-74岁为10.1%,75-79岁为14.8%,80-84岁为25.2%。
  • 65岁以上MCI患者2年累积痴呆发病率为14.9%。

关键数值与推荐

  • 临床医生应在合适场景使用经验证工具评估MCI(B级)。
  • 应评估可调控危险因素、功能损害,并评估和治疗行为/神经精神症状(B级)。
  • 应随时间监测MCI患者认知状态(B级)。
  • 应尽可能停用导致认知损害的藥物并治疗行为症状(B级)。
  • 临床医生可选择不提供胆碱酯酶抑制剂(B级);若提供,必须先讨论证据缺乏(A级)。

临床怎么用

  • 在合适场景用经验证工具筛查评估MCI,并评估可调控危险因素与功能损害。
  • 监测认知状态变化,停用可能损害认知的藥物,治疗行为/神经精神症状。
  • 推荐规律运动,可考虑认知训练;不常规提供胆碱酯酶抑制剂,若提供需先说明证据缺乏。
  • 与患者及家属讨论诊断、预后、长期规划及藥物证据缺乏。
  • 可与患者及家属讨论生物标志物研究。

局限性

  • 无高质量证据支持MCI的藥物治疗。
  • 胆碱酯酶抑制剂缺乏证据,推荐不提供或提供前必须讨论证据缺乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To update the 2001 American Academy of Neurology (AAN) guideline on mild cognitive impairment (MCI). METHODS: The guideline panel systematically reviewed MCI prevalence, prognosis, and treatment articles according to AAN evidence classification criteria, and based recommendations on evidence and modified Delphi consensus. RESULTS: MCI prevalence was 6.7% for ages 60-64, 8.4% for 65-69, 10.1% for 70-74, 14.8% for 75-79, and 25.2% for 80-84. Cumulative dementia incidence was 14.9% in individuals with MCI older than age 65 years followed for 2 years. No high-quality evidence exists to support pharmacologic treatments for MCI. In patients with MCI, exercise training (6 months) is likely to improve cognitive measures and cognitive training may improve cognitive measures. MAJOR RECOMMENDATIONS: Clinicians should assess for MCI with validated tools in appropriate scenarios (Level B). Clinicians should evaluate patients with MCI for modifiable risk factors, assess for functional impairment, and assess for and treat behavioral/neuropsychiatric symptoms (Level B). Clinicians should monitor cognitive status of patients with MCI over time (Level B). Cognitively impairing medications should be discontinued where possible and behavioral symptoms treated (Level B). Clinicians may choose not to offer cholinesterase inhibitors (Level B); if offering, they must first discuss lack of evidence (Level A). Clinicians should recommend regular exercise (Level B). Clinicians may recommend cognitive training (Level C). Clinicians should discuss diagnosis, prognosis, long-term planning, and the lack of effective medicine options (Level B), and may discuss biomarker research with patients with MCI and families (Level C).

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2017. PMID: 29282327. doi:10.1212/WNL.0000000000004826

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。